Navigation Links
HumanZyme® Announces Human Cell-Expressed Interferon beta for Immunology and Immunotherapy Research Applications
Date:8/8/2017

HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine® Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta is a member of the type I family of interferons that activate Th1-type innate immune responses against viral and bacterial infection, and have antiproliferative and immunomodulatory functions. IFN beta is currently FDA-approved in injectable form as a treatment for multiple sclerosis, an autoimmune disease, and has been investigated for use in cancer therapeutics for its anti-tumor activity.

According to Scott Coleridge, CEO at HumanZyme, “We are proud to be the only commercial supplier of high-quality, tag-free recombinant human Interferon beta expressed in human cells for research purposes. Our proprietary HEK293 expression system allows us to express difficult proteins in a human cell line to provide the most authentic recombinant products possible. The new IFN beta further expands our animal component-free HumanKine product line, and the product is priced competitively and also available in bulk.”

Glycosylation of the IFN beta protein by a single asparagine-linked sugar chain is essential to its activity and stability, both in vitro and in vivo. IFN beta purified from human cells has been shown to have the highest biologic activity and stability compared to recombinant human IFN beta produced in non-human expression systems. HumanZyme’s recombinant human IFN beta expressed in human cells assures native processing, glycosylation and folding of the purified protein compared to bacterial, mammalian cell lines, or insect cell expression systems, preserving its biologic function and activity. HumanZyme’s HumanKine proteins are also animal-derived product free, xeno-free and carrier-free.

For more information, see our Interferon beta product page.

About HumanZyme, Inc.:
HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide, from academic and government research institutions to biotechnology and pharmaceutical companies.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14577825.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. HumanZyme® Launches New XKine™ Recombinant Protein Line Expanding Reagents For Stem Cell Research and Regenerative Medicine Applications
2. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
3. Annual Conference about Technology Solutions for People with Disabilities Announces Program
4. Probiotic Action Announces Probiotics Lead the Digestive Health Market
5. Verenium Announces Preliminary Financial Results For Fiscal 2012
6. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
7. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
8. EAG Announces New General Manager of Release-To-Production (RTP) Division
9. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
10. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
11. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to competitively procured purchasing contracts to its membership, recently named BioFit Engineered ... members with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of ... businesses of all types to ensure cleanliness, distancing and occupancy with its patent pending ... Space™ enabled business will provide a health performance index system that scores all aspects ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... today announced the company has entered a license agreement with Roswell Park Comprehensive ... globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kerafast Inc. , developers ... announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The ... of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 ...
Breaking Biology Technology:
(Date:8/3/2020)... , ... August 03, 2020 , ... ... announced a new partnership with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 ... to strengthen their laboratory supply chain for more than 10 years. Early in ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to ... a near term focus on Type 2 diabetes and associated comorbidities. , Justin ... therapeutic areas and classes. As Chief Commercial Officer, Justin will lead Better ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study ... the Invictus Medical Neoasis™ active noise control device to attenuate typical noises in ... Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and other bedside ...
Breaking Biology News(10 mins):